KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Accured Expenses (2016 - 2026)

Neogenomics filings provide 17 years of Change in Accured Expenses readings, the most recent being $718000.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 103.13% to $718000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $19.0 million, a 170.79% increase, with the full-year FY2025 number at -$4.7 million, down 17.22% from a year prior.
  • Change in Accured Expenses hit $718000.0 in Q1 2026 for Neogenomics, down from $6.9 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $30.7 million in Q2 2025 to a low of -$23.0 million in Q1 2025.
  • Median Change in Accured Expenses over the past 5 years was -$138000.0 (2024), compared with a mean of -$628411.8.
  • The widest YoY moves for Change in Accured Expenses: up 1531.4% in 2025, down 16535.51% in 2025.
  • Neogenomics' Change in Accured Expenses stood at $1.8 million in 2022, then crashed by 184.21% to -$1.6 million in 2023, then tumbled by 93.0% to -$3.0 million in 2024, then soared by 328.85% to $6.9 million in 2025, then crashed by 89.56% to $718000.0 in 2026.
  • The last three reported values for Change in Accured Expenses were $718000.0 (Q1 2026), $6.9 million (Q4 2025), and -$19.3 million (Q3 2025) per Business Quant data.